Latest news with #VINIA®
Associated Press
7 days ago
- Business
- Associated Press
BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ('BioHarvest' or the 'Company'), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on . Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike. Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.* 'Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use,' said Ilan Sobel, CEO of BioHarvest. 'The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend. 'This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions,' concluded Sobel. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About Informed Sport Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit . Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Corporate Contact: Dave Ryan, VP Investor Relations +1 (604) 622-1186 [email protected] Investor Relations Contact: Lucas A. Zimmerman Managing Director MZ Group - MZ North America +1 (949) 259-4987 [email protected] To view the source version of this press release, please visit
Yahoo
7 days ago
- Business
- Yahoo
BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike. Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.* "Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use," said Ilan Sobel, CEO of BioHarvest. "The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend. "This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions," concluded Sobel. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About Informed Sport Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Corporate Contact:Dave Ryan, VP Investor Relations+1 (604) 622-1186info@ Investor Relations Contact:Lucas A. ZimmermanManaging DirectorMZ Group - MZ North America+1 (949) 259-4987BHST@ To view the source version of this press release, please visit
Yahoo
15-05-2025
- Business
- Yahoo
BioHarvest Sciences Reports First Quarter 2025 Financial Results
First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management Guidance Rehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.5% of revenue. Management expects second quarter 2025 revenues of at least $8.5 million and expects to reach adjusted EBITDA breakeven in the second half of 2025. Total VINIA® subscribers surpassed 50,000 as of February 2025, with $50M of cumulative revenue realized since launch. Announced completion of Stage 1 development for the Contract Development and Manufacturing Organization (CDMO) contract with a Nasdaq-listed pharmaceutical company, successfully validating the botanical synthesis platform for a variety of molecule types. Announced that in vitro testing shows the Company's proprietary olive cell compound reduces fat accumulation in human liver cells, with the expectation that consumer sales begin in 2026. Presented at leading small-cap investor conferences including the 37th Annual ROTH Conference and the WeBull Consumer Stocks Webinar Management Commentary Ilan Sobel, CEO of BioHarvest Sciences, said: "Our first quarter of 2025 was highlighted by a step change in revenue growth and financial performance with continued momentum in our Products and CDMO business units. Revenues for the quarter again exceeded guidance, increasing 47% to $7.9 million, driven by growth in the VINIA® business which exceeded 50,000 active subscribers as of February 2025. We are aggressively operationalizing our strategy to broaden the reach of VINIA® into new consumer segments with our expanded portfolio of VINIA® product offerings while also reinforcing our core value proposition with existing customers anchored in delivering the multiple benefits of VINIA® for approximately $1 per day. "We continue to expand our VINIA® Inside strategy with additional VINIA® product lines such as VINIA® SuperFood Tea in K Cup® compatible pods, VINIA® Espresso in Nespresso®-compatible pods, and soon to be launched VINIA® 2X Formula Daily Chews, which are addressing a highly incremental, younger consumer base enabling the Company to capture incremental revenue from this important market segment. As part of this effort, we are activating incremental marketing channels, such as podcast integrations, TikTok, and a Health & Wellness Influencer Program. "In our CDMO division, we are accelerating our path to develop, manufacture and democratize life-changing molecules that will improve the Health & Wellness of millions of people while preserving the planet for generations to come. We are using our proven technology capabilities, which now include a robust lab infrastructure and custom AI tools that optimize R&D processes. to develop plant-based non-GMO biologic compounds for pharma, nutraceutical, nutrition and cosmetics companies. We recently announced that our pharma CDMO contract successfully moved to Stage 2 of our R+D process, and we have commenced Stage 1 tissue culture work for our contract with Tate & Lyle to develop a next-generation of non-nutritive plant-based sweetener. Both of these projects serve as major validations of our Botanical Synthesis platform. These agreements lay the groundwork for future expansion into additional high-value molecule categories, leveraging our ability to produce plant-derived compounds sustainably and at scale. In addition to the ongoing agreements, we have a robust near-term contract pipeline, and we are actively advancing discussions with additional strategic partners in other targeted industry verticals, where we expect to sign several additional CDMO clients through year-end. "Looking ahead, we anticipate continued growth in both our Products and Services business units - growing our "VINIA® inside" product lines and subscriber bases and adding new CDMO partners. The need for life-changing compounds, enabled by our proprietary Botanical Synthesis platform, will only accelerate given global consumer health and wellness trends, and our ability to balance profitability with scale ensures we can continue to invest in innovative R&D processes, and AI-driven CDMO efficiencies. Taken together, we believe we are well positioned for further growth and increased shareholder value through a diversified, high-margin business model with significant levels of built-in operating leverage," concluded Sobel. First Quarter 2025 Financial Results All figures stated in this news release are in U.S. dollars unless stated otherwise. Revenues for the first quarter of 2025 increased 47% to $7.9 million - which exceeded management's revenue guidance - as compared to $5.3 million in the first quarter of 2024. The increase was a result of the continued success of the Company's VINIA® family of products. Gross profit increased 53% to $4.6 million, or 58.5% of total revenue, in the first quarter of 2025, as compared to $3.0 million, or 56.2% of total revenue, in the same year-ago quarter. The increase in gross margin was primarily attributable to the benefits of increased manufacturing scale and improved manufacturing yields. Total operating expenses for the first quarter totaled $6.3 million, as compared to $4.4 million in the same year-ago quarter. The increase in operating expenses was primarily due to increased marketing spend which was reduced as a percentage of revenue to 46.8% of revenue, as compared to 48.0% in the same year ago quarter - and higher expenses from the CDMO services division. General and administrative expenses increased 67% in the first quarter but declined by 6% as compared to the fourth quarter of 2024, reflecting increased operating leverage as the Company continues to scale. Net loss for the first quarter of 2025 totaled $2.3 million, or $0.13 per basic and diluted share, as compared to a net loss of $6.6 million, or $0.48 per basic and diluted share, in the same year-ago quarter. Adjusted EBITDA loss - a non-IFRS measure - totaled $1.4 million in the first quarter of 2025, as compared to an adjusted EBITDA loss of $1.1 million in the same year-ago quarter. During the quarter, the Company raised $3.9 million in debt financing, primarily from existing investors. Cash and cash equivalents as of March 31, 2024, totaled $3.4 million, as compared to $2.4 million as of December 31, 2024. First Quarter 2025 Results Conference Call Management will host an investor conference call and webcast at 4:30 p.m. Eastern time today to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information: Date: Thursday, May 15, 2025Time: 4:30 p.m. Eastern timeU.S./Canada Dial-in: 1-877-300-8521International Dial-in: 1-412-317-6026Conference ID: 2552254Webcast: BHST Q1 2025 Earnings Conference Call Please dial in at least 10 minutes before the start of the call to ensure timely participation. A telephone playback of the call will be available through Thursday, May 29, 2025. To listen, call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 10198733. A webcast replay will also be available at the webcast link above. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Use of Non-IFRS Financial Measures This press release includes the following non-IFRS measure - Adjusted EBITDA, which is not a measure of financial performance under IFRS and should not be considered as an alternative to net income as a measure of financial performance. Adjusted EBITDA represents net income (loss) before interest, taxes, depreciation and amortization adjusted for stock-based compensation and fair value adjustment of convertible loan and or warrants as well as issuance of warrants. The company believes this non-IFRS measure, when considered together with the corresponding IFRS measures, provides useful information to investors and management regarding financial and business trends relating to the company's results of operations. However, this non-IFRS measure has significant limitations in that it does not reflect all the costs and other items associated with the operation of the company's business as determined in accordance with IFRS. In addition, the company's non-IFRS measures may be calculated differently and are therefore not comparable to similar measures by other companies. Therefore, investors should consider non-IFRS measures in addition to, and not as a substitute for, or superior to, measures of financial performance in accordance with IFRS. A reconciliation of Adjusted EBITDA to net income, its corresponding IFRS measure, is shown below. IFRS NET INCOME (LOSS) TO ADJUSTED EBITDA RECONCILIATION(Unaudited)(U.S dollars in thousands)Three-month period ended March 31, 2025 2024Net (loss) ($ 2,338 ) ($ 6,581 ) Depreciation and Amortization 399 205 Taxes 38 - Interest, net 361 97 Fair Value adjustment of derivative liability - Convertible loan - 4,618 Fair Value adjustment of derivative liability - Warrants - 408 Share Based Payment 132 133 Adjusted EBITDA (Non-IFRS) ($1,408 ) ($1,120 ) Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. There is no assurance that shareholder value will increase or that the Company will maintain or improve current financial performance, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. Revenue projections are estimates and there is no assurance will occur when estimated as the timing is dependent on consumer acceptance and cost stability and other factors beyond company control. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. There is no assurance that our initiatives such as digitization of production processes, increased capacity bioreactors, and consolidation of operations will enhance profitability which is subject to risks and uncertainties including changes in consumer demand, unexpected cost increases, unanticipated production disruptions and a myriad of other unpredictable factors that may impact profitability. Note: VINIA® has no affiliation with Keurig Dr. Pepper Inc. or Nespresso®. "Keurig®" and "K-Cup®" are registered trademarks of Keurig Dr. Pepper Inc. BioHarvest Corporate Contact:Dave Ryan, VP Investor Relations+1 (604) 622-1186info@ Investor Relations Contact:Lucas A. ZimmermanManaging DirectorMZ Group - MZ North America+1 (949) 259-4987BHST@ BioHarvest Sciences Statements of Financial PositionU.S. dollars in thousandsAs at March 31, 2025 As at December 31,2024 Assets Current assets Cash and cash equivalents $ 3,401 $ 2,390 Trade accounts receivable 1,476 1,116 Other accounts receivable 754 695 Inventory 4,012 3,655 Total current assets 9,643 7,856 Non-current Restricted cash 361 371 Property, plant and equipment, net 7,984 7,750 Right-of-use assets, net 8,603 9,024 Total non-current assets 16,948 17,145 Total assets$ 26,591$ 25,001 Liabilities Current liabilities Trade accounts payable$ 3,734$ 3,525 Other accounts payable 3,817 3,609 Deferred revenue 1,129 906 Lease liabilities 1,057 772 Loans 7,497 3,905 Liability for Agricultural Research Organization 1,482 1,140 Accrued liabilities 217 401 Total current liabilities 18,933 14,258 Non-current liabilities Lease liability 8,534 9,141 Liability to Agricultural Research Organization - 272 Total non-current liabilities 8,534 9,413 Shareholders' equity (deficit) Share capital and contributed surplus 97,880 97,748 Accumulated deficit (98,756 ) (96,418 ) Total Shareholders' equity (deficit) (876 ) 1,330 Total liabilities and shareholders' equity deficit$ 26,591$ 25,001 BioHarvest Sciences Statements of Loss and Other Comprehensive LossU.S. dollars in thousands, except per share dataThree-month period ended March 31, 2025 2024 Revenues $ 7,860 $ 5,344 Cost of revenues 3,265 2,341 Gross profit 4,595 3,003 Operating expenses Research and development 1,245 1,034 Sales and marketing 3,681 2,564 General and administrative 1,388 829 Total operating expenses (6,314 ) (4,427 ) Operating loss (1,719 ) (1,424 ) Finance income - - Finance expenses 581 5,157 Net loss before tax (2,300 ) (6,581 ) Taxes on income 38 - Net loss and comprehensive loss$ (2,338 ) $ (6,581 ) Basic and Diluted loss per share (0.13 ) (*) (0.48 ) Weighted Average Number of Shares Outstanding 17,327,716 (*) 13,745,997 BioHarvest Sciences Statements of Cash FlowsU.S. dollars in thousandsThree months period ended March 31, 2025 2024 Cash flows from operating activities: Net loss $ (2,338) $ (6,581) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and Amortization 399 202 Fair value adjustments of Convertible loans - 4,618 Fair value adjustments of derivative liability - Warrants - 408 Interest over Agricultural Research Organization liability 70 92 Finance expense, net 299 70 Share based payment 132 133 Changes in assets and liabilities items: Change in trade accounts receivable (360 ) 53 Change in other accounts receivable (59 ) (266 ) Change in inventory (357 ) (210 ) Changes in trade accounts payable, other accounts payable and accrued liabilities 563 (134 ) Changes in deferred revenue 224 61 Cash used in operations (1,427 ) (1,554 ) Interest paid - (24 ) Net cash used in operating activities (1,427 ) (1,578 ) Cash flow from investing activities: Purchase of property and equipment (684 ) (222 ) Deposit of restricted cash for bank guarantee, net of drawing 4 - Net cash used in investing activities (680 ) (222 ) Cash flow from financing activities Repayments of lease liabilities (221 ) (129 ) Proceeds from drawing loans, net of repayments 3,343 - Exercise of options and warrants by employees and consultants - 13 Proceeds from issuance of units of securities - - Proceeds from issuance of convertible loans - - Repayments of principal and interest of convertible loans - - Net cash (used in) provided by financing activities 3,122 (116 ) Exchange rate differences on cash and cash equivalents (4 ) (3 ) Increase (decrease) in cash and cash equivalents 1,015 (1,916 ) Cash and cash equivalents at the beginning of the year 2,390 5,355 Cash and cash equivalents at the end of the year$ 3,401 $ 3,436 Significant non-cash transactions: Conversion of Convertible loans into shares - 17,170 To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-03-2025
- Health
- Yahoo
BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells
Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for BioHarvest's Future Olive Cell Product Targeting Liver Health Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced new 'in vitro' test results for the Company's proprietary new Olive Cell compound, which showed reduced fat accumulation in human liver cells. Fat accumulation in the liver is a leading cause of non-alcohol fatty liver disease (NAFLD), which affects 30-40% of U.S. adults*. BioHarvest demonstrated that in human hepatic (liver) cells, the Olive Cell compound mitigated fat accumulation in a liver steatosis model as well as in experimental models of liver fibrosis. In addition, the Olive Cell compound also succeeded in reducing the level of collagen type 1 in XL-2 cells in an in-vitro fibrosis model. The Company attributes the positive test results of reducing fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for a variety of effects on the liver) in BioHarvest's Olive Cell compound. Hepatic fat accumulation can progress from simple NAFLD to non-alcoholic steatohepatitis (NASH) which includes hepatocellular injury, inflammation, and fibrosis. In more severe cases, complications such as liver cirrhosis and hepatocellular carcinoma may arise. NASH, the more severe form of NAFLD, affects 3-5% of US adult population. There are currently limited FDA-approved drugs specifically for NAFLD. Based on these results and additional studies to be conducted in 2025, the Company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product, while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its CDMO model. The Company anticipates that this Olive Cell product will contain the highest levels of Verbascoside produced from olives in the global market. This unique compound was analyzed by Professor Maurizio Servili from University of Perugia, Italy, a leading worldwide expert of olive polyphenols. BioHarvest's Botanical Synthesis platform elicits and magnifies plant-produced molecules like Verbascoside and produces them in non-GMO plant cells at industrial scale. The Olive product will join VINIA® as part of the Company's portfolio. VINIA®, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow. The Company recently announced that VINIA® had surpassed $50M USD in sales, with over 50,000 active subscribers. "Non-alcoholic fatty liver disease impacts over 100 million Americans, and as part of our mission to develop life-changing compounds from plants, we believe our Olive Cell Product will have the capacity to be a next-generation therapeutic solution for improving liver health in millions of American consumers," said Ilan Sobel, CEO of BioHarvest. "This product will be accretive to our nutraceuticals portfolio and will allow us to realize significant marketing and sales synergies with VINIA®, which has already over 50,000 active subscribers today." "in vitro" Testing Details In these BioHarvest tests, 'in vitro' models on human hepatic cells demonstrated that the Olive Cell compound mitigated fat accumulation in a liver steatosis model as well as in experimental models of liver fibrosis. The tests were conducted using an in-vitro model of Oleic acid (OA)-induced lipid accumulation in HepG2 cells, which is commonly used as a model for studying NAFLD. In addition to mitigating lipid accumulation in the liver steatosis model, the Olive Cell compound also succeeded in reducing the level of collagen type 1 in XL-2 cells in an in-vitro fibrosis model. About VINIA® VINIA® is the first commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA® contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol. VINIA® significantly dilates arteries by increasing Nitric Oxide levels in the blood (which act as a vasodilator) and by reducing the Endothelin-1 levels in the blood (which act as a vasoconstrictor). VINIA® currently has over 8,000 verified online reviews and an average 4.8/5** consumer rating. To learn more, please visit * **BioHarvest encourages all customers to leave honest and uncensored feedback. Customers receive a 30-day supply when they submit a review, whether positive or negative. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Forward-Looking Statements This press release may contain "forward-looking statements". "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." In particular , without limiting the generality of the foregoing, there is no assurance that the company will be able to partner with a pharmaceutical company to develop an FDA approved drug , such event is subject to uncertainties such as limited budgets for this type of drug development, acceptance by pharmaceutical company scientists of the potential for the compound as a drug and the potential market for the drug as well as the usual uncertainties related to clinical trials. In addition there is no assurance that the successful marketing program for Vinia will achieve the same or similar results for the olive cell product as such result depends on consumer preferences, consumer acceptance of potential health benefits, pricing and other similar factors. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and any other risks identified in other filings made by the Company with the Securities and Exchange Commission". This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents. BioHarvest Corporate Contact:Dave Ryan, VP Investor Relations+1 (604) 622-1186info@ Investor Relations Contact:Lucas A. ZimmermanManaging DirectorMZ Group - MZ North America+1 (949) 259-4987BHSC@ To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
04-03-2025
- Health
- Associated Press
BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells
Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for BioHarvest's Future Olive Cell Product Targeting Liver Health Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ('BioHarvest' or 'the Company'), a company pioneering its patented Botanical Synthesis technology process, today announced new 'in vitro' test results for the Company's proprietary new Olive Cell compound, which showed reduced fat accumulation in human liver cells. Fat accumulation in the liver is a leading cause of non-alcohol fatty liver disease (NAFLD), which affects 30-40% of U.S. adults*. BioHarvest demonstrated that in human hepatic (liver) cells, the Olive Cell compound mitigated fat accumulation in a liver steatosis model as well as in experimental models of liver fibrosis. In addition, the Olive Cell compound also succeeded in reducing the level of collagen type 1 in XL-2 cells in an in-vitro fibrosis model. The Company attributes the positive test results of reducing fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for a variety of effects on the liver) in BioHarvest's Olive Cell compound. Hepatic fat accumulation can progress from simple NAFLD to non-alcoholic steatohepatitis (NASH) which includes hepatocellular injury, inflammation, and fibrosis. In more severe cases, complications such as liver cirrhosis and hepatocellular carcinoma may arise. NASH, the more severe form of NAFLD, affects 3-5% of US adult population. There are currently limited FDA-approved drugs specifically for NAFLD. Based on these results and additional studies to be conducted in 2025, the Company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product, while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its CDMO model. The Company anticipates that this Olive Cell product will contain the highest levels of Verbascoside produced from olives in the global market. This unique compound was analyzed by Professor Maurizio Servili from University of Perugia, Italy, a leading worldwide expert of olive polyphenols. BioHarvest's Botanical Synthesis platform elicits and magnifies plant-produced molecules like Verbascoside and produces them in non-GMO plant cells at industrial scale. The Olive product will join VINIA® as part of the Company's portfolio. VINIA®, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow. The Company recently announced that VINIA® had surpassed $50M USD in sales, with over 50,000 active subscribers. 'Non-alcoholic fatty liver disease impacts over 100 million Americans, and as part of our mission to develop life-changing compounds from plants, we believe our Olive Cell Product will have the capacity to be a next-generation therapeutic solution for improving liver health in millions of American consumers,' said Ilan Sobel, CEO of BioHarvest. 'This product will be accretive to our nutraceuticals portfolio and will allow us to realize significant marketing and sales synergies with VINIA®, which has already over 50,000 active subscribers today.' 'in vitro' Testing Details In these BioHarvest tests, 'in vitro' models on human hepatic cells demonstrated that the Olive Cell compound mitigated fat accumulation in a liver steatosis model as well as in experimental models of liver fibrosis. The tests were conducted using an in-vitro model of Oleic acid (OA)-induced lipid accumulation in HepG2 cells, which is commonly used as a model for studying NAFLD. In addition to mitigating lipid accumulation in the liver steatosis model, the Olive Cell compound also succeeded in reducing the level of collagen type 1 in XL-2 cells in an in-vitro fibrosis model. About VINIA® VINIA® is the first commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA® contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol. VINIA® significantly dilates arteries by increasing Nitric Oxide levels in the blood (which act as a vasodilator) and by reducing the Endothelin-1 levels in the blood (which act as a vasoconstrictor). VINIA® currently has over 8,000 verified online reviews and an average 4.8/5** consumer rating. To learn more, please visit **BioHarvest encourages all customers to leave honest and uncensored feedback. Customers receive a 30-day supply when they submit a review, whether positive or negative. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Forward-Looking Statements This press release may contain 'forward-looking statements'. 'Forward-looking statements' describe future expectations, plans, results, or strategies and are generally preceded by words such as 'may,' 'future,' 'plan' or 'planned,' 'will' or 'should,' 'expected,' 'anticipates,' 'draft,' 'eventually' or 'projected.' In particular , without limiting the generality of the foregoing, there is no assurance that the company will be able to partner with a pharmaceutical company to develop an FDA approved drug , such event is subject to uncertainties such as limited budgets for this type of drug development, acceptance by pharmaceutical company scientists of the potential for the compound as a drug and the potential market for the drug as well as the usual uncertainties related to clinical trials. In addition there is no assurance that the successful marketing program for Vinia will achieve the same or similar results for the olive cell product as such result depends on consumer preferences, consumer acceptance of potential health benefits, pricing and other similar factors. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and any other risks identified in other filings made by the Company with the Securities and Exchange Commission'. Lucas A. Zimmerman Managing Director MZ Group - MZ North America
